Db/db 마우스 모델에 있어서 한약재조성물의 혈당 및 혈장 콜레스테롤 개선효과
Amelioration of Plasma Glucose and Cholesterol levels in Db/db Mice by a Mixture of Chinese Herbs
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Diabetes mellitus is the fifth leading cause of death among Koreans. Control of hyperglycemia and dyslipidemia is strongly correlated with decrease in risks for cardiovascular diseases, the most common and fatal diabetic complication. The effects of chronic feeding of a mixture of Chinese herbs on blood lipid profile were measured in an animal model of type 2 diabetes mellitus, db/db mice (C57BL/Ks). The Chinese herb mixture was composed of Panax ginseng C. A. Meyer, Astragalus membranaceus, Glycyrrhiza uralensis, Lycium chinense, Morus, Pueraria thunbergiana, Prunella vulgaris var. lilacina, Acanthopanax sessiliflorus, Schizandra chinensis, Scutellaria baicalensis, Dioscorea batatas, Polygonatum doratum var. pluriflorum, Paeonia lactiflora, and Rehmannia glutinosa in a ratio of 1 : 0.7 : 0.4 : 0.7 : 0.4 : 0.7 : 1.1 : 0.9 : 0.4 : 0.4 : 0.7 : 0.7 : 0.9 : 0.9. Methanol extract of the Chinese herb mixture was tested for the inhibitory activity against yeast α-glucosidase in vitro. The Chinese herb mixture extract inhibited α-glucosidase by 25.2% at the concentration of 0.5㎎/mL. Four weekold male db/db mice (n = 14) were fed AIN-93G semipurified diet or diet containing 10% powder of the Chinese herb mixture for 6 weeks after 1 week of adaptation period. Body weight (39.5 ± 1.6 g) and food intake (4.3 ± 0.6 g/day) of the Chinese herb group were not significantly different from those of the control group (40.4 ± 2.6 g and 4.5 ± 0.6 g/day). Consumption of Chinese herb mixture significantly decreased plasma glucose level (442.5 ± 36.0㎎/dL) compared with the control group (489.8 ± 34.6 ㎎/dL, p < 0.05). Plasma cholesterol level (159.2 ± 18.4 ㎎/dL) of the Chinese herb group was significantly lower than that of the control group (185.4 ± 13.7 ㎎/dL, p < 0.05). Blood glycated hemoglobin (6.3 ± 0.8%) and plasma triglyceride levels (99.4 ± 15.0㎎/dL) of the Chinese herb group were not significantly different from those of the control group (6.7 ± 0.7% and 108.8 ± 11.0㎎/dL). Thus, the Chinese herb mixture could be useful in the treatment of diabetes and cardiovascular complications of diabetes.
Abstract
Diabetes mellitus is the fifth leading cause of death among Koreans. Control of hyperglycemia and dyslipidemia is strongly correlated with decrease in risks for cardiovascular diseases, the most common and fatal diabetic complication. The effects of chronic feeding of a mixture of Chinese herbs on blood lipid profile were measured in an animal model of type 2 diabetes mellitus, db/db mice (C57BL/Ks). The Chinese herb mixture was composed of Panax ginseng C. A. Meyer, Astragalus membranaceus, Glycyrrhiza uralensis, Lycium chinense, Morus, Pueraria thunbergiana, Prunella vulgaris var. lilacina, Acanthopanax sessiliflorus, Schizandra chinensis, Scutellaria baicalensis, Dioscorea batatas, Polygonatum doratum var. pluriflorum, Paeonia lactiflora, and Rehmannia glutinosa in a ratio of 1 : 0.7 : 0.4 : 0.7 : 0.4 : 0.7 : 1.1 : 0.9 : 0.4 : 0.4 : 0.7 : 0.7 : 0.9 : 0.9. Methanol extract of the Chinese herb mixture was tested for the inhibitory activity against yeast α-glucosidase in vitro. The Chinese herb mixture extract inhibited α-glucosidase by 25.2% at the concentration of 0.5㎎/mL. Four weekold male db/db mice (n = 14) were fed AIN-93G semipurified diet or diet containing 10% powder of the Chinese herb mixture for 6 weeks after 1 week of adaptation period. Body weight (39.5 ± 1.6 g) and food intake (4.3 ± 0.6 g/day) of the Chinese herb group were not significantly different from those of the control group (40.4 ± 2.6 g and 4.5 ± 0.6 g/day). Consumption of Chinese herb mixture significantly decreased plasma glucose level (442.5 ± 36.0㎎/dL) compared with the control group (489.8 ± 34.6 ㎎/dL, p < 0.05). Plasma cholesterol level (159.2 ± 18.4 ㎎/dL) of the Chinese herb group was significantly lower than that of the control group (185.4 ± 13.7 ㎎/dL, p < 0.05). Blood glycated hemoglobin (6.3 ± 0.8%) and plasma triglyceride levels (99.4 ± 15.0㎎/dL) of the Chinese herb group were not significantly different from those of the control group (6.7 ± 0.7% and 108.8 ± 11.0㎎/dL). Thus, the Chinese herb mixture could be useful in the treatment of diabetes and cardiovascular complications of diabetes.
참고문헌 (35)
- Official methods of analysis. 14th ed, "A.O.A.C", Association of official analytical chemists. Washington DC, USA, ~ (1995)
- Diabetes surveillance report, "Centers for disease control and prevention", GA: US Department of Health and Human Services. Atlanta, ~ (1999)
- Coniff RF, "Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM", Diabetes Care, 18, pp.817~824 (1995)
- Fujita H, "Fermented soybean-derived touchiextract with anti-diabetic effect via alpha-glucosidase inhibitory action in a long-term administration study with KKAy mice", Life Sci, 70, pp.219~227 (2001)
- Gonuth SM, "Plasma insulin and glucose profiles in normal, obese and diabetic persons", Ann. Intern. Med, 79, pp.812~822 (1973)
- Hanefeld M, "The role of acarbose in the treatment of noninsulin- dependent diabetes mellitus", J. Diabetes Complicat, 12, pp.228~237 (1998)
- Hermansen K, "Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects", Diabetes Care, 24, pp.228~233 (2001)
- Hillebrand I, "The effects of the alpha-glucosidase inhibitor BAYg5421(Acarbose) on mealstimulated elevations of circulating glucose, insulin and triglyceride levels in man", Res. Exp. Med, 175, pp.81~86 (1979)
- Holman RR, "A randomized doubleblind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years. (U.K. Prospective Diabetes Study 44)", Diabetes Care, 22, pp.960~964 (1999)
- Kannel WB, "Diabetes and cardiovascular disease The framingum study.", J.A.M.A, 241, pp.2035~2038 (1979), 2035-2038.
- King H, "Global burden of diabetes. 1995-2025: prevalence, numerical estimates, and projections", Diabetes Care, 21, pp.1414~1431 (1998)
- Koivisto VA, "Insulin therapy in type II diabetes", Dia-betes Care, 16, pp.29~39 (1993)
- The cause of death Statistics 2005. Annual report of on the cause of death statistics, "Korea National Statistical Office", Korea National Statistical Office, ~ (2005)
- Lebovitz HE, "α-Glucosidase inhibitors as agents in the treatment of diabetes", Diabetes Rev, 6, pp.132~145 (1998)
- Lim SJ, "Hypoglycemic effect of Polygonatum Odoratum var. Pluriflorum Ohwi extract in streptozotocininduced diabetic rats", Korean J. Nutr, 28, pp.727~736 (1995)
- Lim SJ, "Hypoglycemic and hypotensive effects of Polygonatum odoratum consumption in non-insulin dependent diabetics mellitus patients", Korean J. Soc. Food Sci, 13, pp.47~55 (1997)
- Meneilly GS, "Effect of acarbose on insulin sensitivity in elderly patients with diabetes", Diabetes Care, 23, pp.1162~1167 (2000)
- Miettinen H, "Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group", Diabetes Care, 21, pp.69~75 (1998)
- Mughal MA, "Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes", J. Pak. Med. Assoc, 50, pp.152~156 (2000)
- Musabayane CT, "Effects of oral administration of some herbal extracts on food consumption and blood glucose levels in normal and streptozotocin-treated diabetic rats", Methods Find. Exp. Clin. Pharmacol, 28, pp.223~228 (2006)
- Nishioka T, "Baicalein, an alphaglucosidase inhibitor from Scutellaria baicalensis", J. Nat. Prod, 61, pp.1413~1415 (1998)
- Oku T, "Inhibitory effects of extractives from leaves of Morus alba on human and rat small intestinal disaccharidase activity", Br. J. Nutr, 95, pp.933~938 (2006)
- 이현화, "여주 추출물의 항산화 활성", 한국약용작물학회지, 15(1), pp.56~61 (2007), 한국약용작물학회
- Prosky L, "Determination of insoluble, soluble, and total dietary fiber in foods and food products: interlaboratory study", J. Assoc. Off. Anal. Chem, 71, pp.1017~1023 (1988)
- Qualmann C, "Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)", Scand. J. Gastroenterol, 30, pp.892~896 (1995)
- Seifarth C, "Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients", Diabet. Med, 15, pp.485~491 (1998)
- Stamler J, "Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial", Diabetes Care, 16, pp.434~444 (1993)
- Stand E, "Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy", Diabetes Obes. Metab, 10, pp.215~220 (1999)
- The diabetes control and complications trial research group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N. Engl. J. Med, 329, pp.977~986 (1993)
- Toeller M, "Alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects", Eur. J. Clin. Invest, 24(S)(3), pp.31~35 (1994)
- UK Prospective diabetes study (UKPDS) Group, "Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes", Lancet, 352, pp.837~853 (1998)
- Wang BT, "Xinbian meirong bencao" (2006), Military medicine science publishing co., China.
- Watanabe J, "Isolation and identification of α-glucosidase inhibitors from Tochu-cha", Biosci. Biotechi. Biochem, 61, pp.177~178 (1997)
- Wright BE, "Positive effects of acarbose in the diabetic rat are not altered by feeding schedule", Phys. Behavior, 63, pp.867~874 (1998)
- Zavaroni I, "Inhibition of carbohydrateinduced hypertriglyceridemia by a disaccharidase inhibitor", Metabolism, 30, pp.417~420 (1981)